BeiGene, Ltd. (NASDAQ:BGNE – Get Rating) CEO John Oyler sold 30,520 shares of the stock in a transaction on Tuesday, September 20th. The shares were sold at an average price of $153.50, for a total value of $4,684,820.00. Following the sale, the chief executive officer now owns 2,070,913 shares in the company, valued at $317,885,145.50. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

BeiGene Stock Performance

NASDAQ BGNE traded down $4.82 on Thursday, hitting $144.03. 251,608 shares of the company traded hands, compared to its average volume of 286,899. The company has a market capitalization of $14.93 billion, a price-to-earnings ratio of -7.05 and a beta of 0.65. The company has a current ratio of 4.54, a quick ratio of 4.35 and a debt-to-equity ratio of 0.03. The business's 50 day moving average price is $174.23 and its 200-day moving average price is $167.78. BeiGene, Ltd. has a 52-week low of $118.18 and a 52-week high of $392.30.

BeiGene (NASDAQ:BGNE – Get Rating) last released its earnings results on Thursday, August 4th. The company reported ($5.56) earnings per share for the quarter, missing the consensus estimate of ($4.23) by ($1.33). The company had revenue of $341.57 million for the quarter, compared to analysts' expectations of $297.28 million. BeiGene had a negative net margin of 187.65% and a negative return on equity of 38.58%. Equities analysts expect that BeiGene, Ltd. will post -17.02 earnings per share for the current year.

Institutional Investors Weigh In On BeiGene

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on the company. StockNews.com upgraded BeiGene from a "sell" rating to a "hold" rating in a research note on Monday, August 8th. Morgan Stanley dropped their price target on BeiGene from $300.00 to $293.00 and set an "overweight" rating on the stock in a research note on Friday, July 15th. Finally, JPMorgan Chase & Co. restated an "overweight" rating and issued a $296.00 price target on shares of BeiGene in a research note on Tuesday, August 9th. Two equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $299.25.

BeiGene Company Profile

(Get Rating)

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC).

Read More

• Get a free copy of the StockNews.com research report on BeiGene (BGNE)
• The Institutions Hold On To Darden Restaurants International
• What Steelcase's Earnings Say About the Return to the Office?
• Is The Golden Age Of Homebuilding Already Over?
• These 3 Big Dividend Payers Also Boast Strong Price Growth
• Natural Gas Prices Continue To Rally, These Stocks Should Benefit

Receive News & Ratings for BeiGene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BeiGene and related companies with MarketBeat.com's FREE daily email newsletter.